BUSINESS
Thermo Fisher invests Rs 160 crore to expand Bengaluru R&D centre
The expansion is expected to create over 100 high-skilled jobs in the coming years.
BUSINESS
Manipal Group-backed Stempeutics bags first of its kind stem cell treatment deal in Japan
Medinet will develop and commercialize Stempeucel in Japan, pending regulatory clearance, and receive an upfront payment with additional milestone and royalty if the Tokyo-listed firm exercises the option to license the product
BUSINESS
How Eli Lilly’s weight-loss drug Mounjaro gained early lead against Novo Nordisk’s Wegovy in India
Eli Lilly’s blockbuster drug Mounjaro has quickly become the market leader in the segment, thanks to its strong clinical performance and early entry advantage.
BUSINESS
Dr Reddy’s bets on three key launches to offset US price erosion
“Semaglutide, denosumab and abatacept are the three molecules that will help us mitigate the impact of declining Revlimid sales and bring back growth momentum,” said M.V. Narasimham, Chief Financial Officer, in a post-earnings interview.
BUSINESS
Eli Lilly allows Cipla to sell weight loss drug 'Tirzepatide' under new brand in India
Under the agreement, Cipla will market the drug under a new brand name, Yurpeak, while Lilly continues to sell it as Mounjaro, launched earlier this year.
BUSINESS
Laurus Labs posts Rs 195 crore net profit in Q2FY26 led by CDMO, generics momentum
The surge in profitability was underpinned by a 35% rise in revenues to ₹1,653 crore and a 136% jump in EBITDA to ₹429 crore, lifting margins to 26% from 14.9% a year earlier.
BUSINESS
Indian CRDMOs eye growth as US Biosecure Act and US-China trade tensions may redraw supply chains
India’s CRDMO sector, currently valued at $3–3.5 billion, accounts for just 2–3% of the $140–145 billion global market. But with a 15% CAGR from 2019 to 2024—double the global average—the industry is at an inflection point.
BUSINESS
RPG Life Sciences eyes strategic acquisitions as cash-rich balance sheet fuels expansion plans
The pharma firm, part of the RPG Group, is leveraging its robust balance sheet to explore inorganic growth across APIs, formulations, and emerging therapeutic trends.
BUSINESS
Strides Pharma ties-up with Bangladesh's Incepta to launch long-acting contraceptive in Africa
The WHO prequalification of the product, developed by Incepta with support from the Children’s Investment Fund Foundation (CIFF) and the Gates Foundation, breaks the single-source supply chain for DMPA-SC, enabling health systems to procure the drug at more affordable prices.
BUSINESS
Supreme Court dismisses Roche's petition to restrain Natco from selling Risdiplam generic
A bench comprising Justice PS Narasimha and Justice Atul S Chandurkar declined to interfere with the Delhi High Court's order, observing that it was only an interim order.
BUSINESS
Biocon Biologics, Civica ink deal to launch low-cost insulin glargine in US
Under the multi-year agreement, Biocon Biologics will manufacture and supply insulin glargine to Civica, which will commercialize the product under its own label.
BUSINESS
Graph AI secures $3 mn from Bessemer to automate drug safety monitoring
The company’s flagship product, Graph Safety, uses context-aware AI to automate the detection and reporting of adverse drug events (ADEs), a process traditionally handled by large teams of pharmacology graduates manually combing through call transcripts, legal filings, and medical literature.
BUSINESS
Single-specialty healthcare in India draws billions in investor capital, to become $31 billion by 2028
The single-specialty healthcare market, valued at Rs 126,000 crore ($15 billion) in 2024, is projected to surge to Rs 264,000 crore ($31 billion) by 2028, growing at a compound annual growth rate (CAGR) of 20 percent.
BUSINESS
Jupiter Life Line in Rs 1,400-crore expansion push in Maharashtra, to double capacity by 2029
As demand for quality specialist care grows in underserved urban clusters, the hospital chain plans increase the bed count from 1,061 to 2,500, CEO Ankit Thakker tells Moneycontrol
TRENDS
GSK calls for urgent focus on adult vaccination as ageing populations face rising disease burden
Data presented at the event showed that RSV is responsible for nearly 200,000 deaths and 2 million hospitalisations among adults aged over 60 in India alone over a five-year period.
BUSINESS
Everstone-backed Integris Medtech files for Rs 3,500-4,000 crore IPO
India’s second-largest coronary stent maker eyes debt reduction, global growth; FY25 adjusted profit jumps nearly 5x
BUSINESS
How tainted cough syrups slip through India’s broken drug oversight
India’s drug regulation system is split between the central and state governments, which often leads to confusion and weak enforcement.
BUSINESS
Indian patients demand transparency, willing to pay more for certified quality says FICCI & EY-Parthenon report
The findings, outlined in the ‘True Accountable Care’ report released (FICCI) and EY-Parthenon on Thursday, underscore a growing clamour for a national framework that establishes clear quality standards, moving the system beyond informal, word-of-mouth-based decisions.
BUSINESS
Roche faces setback as Delhi high court clears Natco Pharma's low cost generic Risdiplam
The court dismissed Roche’s plea for an injunction, citing public interest and the need for affordable access to the drug, which currently retails at over ₹600,000 per bottle under Roche’s brand name Evrysdi.
BUSINESS
Cough syrup deaths: Old regulatory failures resurface as CDSCO calls for ‘strict quality control’
The directive is similar to the one issued after India-made cough syrups were blamed for deaths of children in Gambia and Uzbekistan even as Coldrif toll climbs to 22 after two more children die
BUSINESS
Health adtech player Indegene rides Trump pharma shakeup with AI-driven outreach
'Whenever the pharma industry is under pressure, those are better times for us,' says CEO Manish Gupta
BUSINESS
Weight-loss drug Mounjaro is India's second-highest selling pharma brand
Mounjaro recorded sales of Rs 85 crore in September. Analysts say user-friendly pen formulation helped build the momentum, expected to get a further boost from GST cuts
BUSINESS
USFDA to fast-track review of generics tested and made in US, but do Indian drugmakers need to worry?
The move is part of a broader push to onshore pharmaceutical production and reduce reliance on foreign suppliers, particularly from India and China.
BUSINESS
Centre proposes Rs 5,000 crore R&D booster for Pharma and MedTech: Can it drive innovation?
The initiative, backed by a total financial outlay of Rs 5,000 Crore (nearly $600 million) spanning from FY 2023-24 to FY 2029-30, is designed to shift the life sciences economy from a volume-driven, cost-based generic manufacturing hub to an innovation-centric global competitor.
